{'fraction_non_alphanumeric': 0.02668213457076566, 'fraction_numerical': 0.00580046403712297, 'mean_word_length': 5.488721804511278, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
N‐Ras Mutation in acute myeloid leukemia: Incidence, prognostic significance and value as a marker of minimal residual disease

Summary The polymerase chain reaction (PCR) and allele specific oligonucleotide (ASO) hybridization have been used to investigate the incidence of N‐ras mutation in acute myeloid leukemia (AML). The prognostic significance of these mutations and their value as markers of minimal residual disease have also been assessed. Mutated N‐ras alleles were detected in 9 of 69 AML patients (13%). No significant difference in survival or remission duration was found between those patients with an N‐ras mutation and those without. Four patients with N‐ras mutations at presentation were followed through disease progression. The results showed no consistent pattern of association between the presence of an N‐ras mutation and disease state.